阿托伐他汀钙治疗慢性充血性心力衰竭患者临床研究  

The clinical study of atorvastatin calcium in the treatment of chronic congestive heart failure

作　　者：朱铁峰 蒋卫华 徐微懿 Zhu Tiefeng Jiang Weihua Xu Weiyi(Department of the First Internal Medicine, the Second People＇s Hospital of Wuc~eng District ,Jinhua ,Zhejiang 321025, China)

机构地区：[1]金华市婺城区第二人民医院内一科,浙江省金华321025

出　　处：《中国基层医药》2017年第12期1845-1848,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 探讨阿托伐他汀钙治疗慢性充血性心力衰竭（CHF）的临床疗效.方法 选择CHF患者132例,根据入院顺序按照单双数随机分为对照组和研究组,两组各66例.对照组进行常规治疗;研究组患者在常规基础上,应用阿托伐他汀钙进行治疗.评估患者临床疗效、检测治疗前后血清胆固醇（TC）;采用超声心动图评估患者治疗前后左心室射血分数（LVEF）、心脏左心室舒张末内径（LVDD）及心脏指数（CI）.观察治疗过程中的不良反应.结果 研究组总有效率为92.42%,高于对照组的83.33%,差异有统计学意义（x2=9.35,P〈0.05）;研究组治疗后血清TC为（3.24±0.75）mmol/L,低于对照组的（4.70±0.86）mmol/L,差异有统计学意义（t=8.96,P〈0.05）;研究组治疗后LVEF为（46.39±6.35）%,高于对照组的（44.60±5.82）%,差异有统计学意义（t=9.47,P〈0.05）;研究组治疗后LVDD和CI分别为（47.06±5.39）mm和（2.60±0.62）L·min-1·m-1,低于对照组的（49.53±6.17）mm和（2.97±0.69）L·min-1·m-1,差异均有统计学意义（t=10.31、9.40,均P〈0.05）.两组不良反应发生率差异无统计学意义（x2=2.04,P〉0.05）.结论 常规治疗基础上应用阿托伐他汀钙治疗CHF,临床疗效显著,患者TC显著降低,心功能改善明显,且具有较高的安全性.Objective To explore the clinical efficacy of atorvastatin calcium in the treatment of chronic congestive heart failure（CHF）.Methods According to the order of admission with single and double,132 CHF patients were randomly divided into control group and study group,66 cases in each group.The control group was given routine treatment,and the study group was treated with atorvastatin calcium on the basis of routine treatment.The clinical efficacy was assessed.Before and after treatment,the serum TC level was measured,the left ventricular ejection fraction（LVEF） and heart left ventricular end diastolic diameter（LVDD）,heart index（CI） were assessed by echocardiography.The adverse reactions during treatment were observed.Results The total effective rate of the study group was 92.42%,which was higher than 83.33% of the control group,the difference was statistically significant（x2=9.35,P〈0.05）.The serum TC of the study group after treatment was （3.24±0.75）mmol/L,which was lower than （4.70±0.86）mmol/L of the control group,the difference was statistically significant（t=8.96,P〈0.05）.The level of LVEF of the study group after treatment was （46.39±6.35）%,which was higher than （44.60±5.82）% of the control group,the difference was statistically significant（t=9.47,P〈0.05）.The levels of LVDD and CI were （47.06±5.39）mm and （2.60±0.62）L·min-1·m-1 respectively,which were lower than （49.53±6.17）mm and （2.97±0.69）L·min-1·m-1 of the control group,the differences were statistically significant（t=10.31,9.40,all P〈0.05）.There was no significant difference in adverse reactions between the two groups（x2=2.04,P〉0.05）.Conclusion Atorvastatin calcium in the treatment of CHF patients on the basis of routine treatment has better clinical effect.It can significantly reduce TC and significantly improve cardiac function,and has high safety.

关 键 词：心力衰竭 阿托伐他汀钙 胆固醇 心脏功能试验 

分 类 号：R541.61[医药卫生—心血管疾病]